RecruitingNCT06673043

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

Studying Autosomal systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: Anifrolumab(drug)
Enrollment: 100 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2028

Study locations (11)

Research Site, Bydgoszcz, Poland
Research Site, Bytom, Poland
Research Site, Gdansk, Poland
Research Site, Katowice, Poland
Research Site, Krakow, Poland
Research Site, Lodz, Poland
Research Site, Lublin, Poland
Research Site, Poznan, Poland
Research Site, Rzeszów, Poland
Research Site, Warsaw, Poland
Research Site, Wroclaw, Poland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06673043 on ClinicalTrials.gov

Other trials for Autosomal systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Autosomal systemic lupus erythematosus →

← Back to all trials